JNJ250117C147000
- 0.09
- 0.000.00%
Johnson & Johnson Newsroom
Barclays Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $166
Unusual Options Activity: JNJ, TSM and Others Attract Market Bets, JNJ V/OI Ratio Reaches 384.6
EST Jan 27th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
J&J Talc Claimants Urge Judge to Reject $8B Settlement, Bankruptcy Plan
Express News | J&J-Backed Medtech Firm Histosonics Considers US IPO; Histosonics May Seek a Valuation of Several Billion Dollars - Bloomberg News
10 Health Care Stocks With Whale Alerts In Today's Session
Salesforce, Johnson & Johnson Share Gains Contribute To Dow's Nearly 150-Point Jump
Barclays Adjusts Johnson & Johnson's Price Target to $166 From $159, Keeps Equalweight Rating
FDA Accepts Teva, Alvotech BLAs for Simponi Biosimilars
After the Bank of Japan rarely indicated an interest rate hike, the market may return to uncertainty.
To avoid being led by the market and given the uncertainty in the economic outlook, the Bank of Japan may restore ambiguous policy guidance.
Over 80% Companies Deliver EPS Wins This Week-Earnings Scorecard
Argus Research Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $185
Argus Research Sticks to Their Buy Rating for Johnson & Johnson (JNJ)
Is Johnson & Johnson (JNJ) the Best Diversified Dividend Stock to Buy Now?
Daiwa Adjusts Price Target on Johnson & Johnson to $150 From $170, Maintains Neutral Rating
Express News | Bio-Thera Solutions: The marketing authorization application for BAT2506 (Golimumab) injection has been accepted by the European EMA.
Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Announces Target Price $169
Disasters Spawn New Businesses. The California Wildfires Will Do the Same. -- Barrons.com
Johnson & Johnson (JNJ.US) Nipocalimab significantly improves the lives of patients with myasthenia gravis and is expected to be approved this year.
Within 24 weeks, patients treated with nipocalimab showed statistically significant and clinically meaningful improvements in their daily activity scores for gMG disease indicators (MG-ADL).
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Johnson & Johnson Likely to Achieve 2025 Targets, RBC Says